Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision use of tolvaptan for volume management in non-dialysis kidney disease with fluid retention
ChiCTR2300075274Phase 4Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tolvaptan in acute kidney failure (AKF) and chronic kidney disease (CKD) (3 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Weight. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
tolvaptan
03
Conditions
acute kidney failure (AKF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2300075274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075274.